Karyopharm Therapeutics Inc. (KPTI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 50M 100M 150M Q3 '21: 37.7M Q4 '21: 126.3M Q1 '22: 47.7M Q2 '22: 39.7M Q3 '22: 36.1M Q4 '22: 33.6M Q1 '23: 38.7M Q2 '23: 37.6M Q3 '23: 36M Q4 '23: 33.7M Q1 '24: 33.1M Q2 '24: 42.8M Q3 '24: 38.8M Q4 '24: 30.5M Q1 '25: 30M Q2 '25: 37.9M Q3 '25: 44M Q4 '25: 34.1M Q1 '26: 35.1M Q2 '26: 33.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 5M 10M 15M Q3 '19: 12.1M Q3 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -43.8M Q4 '21: 47M Q1 '22: -34.6M Q2 '22: -42.9M Q3 '22: -30.8M Q4 '22: -33.9M Q1 '23: -30.9M Q2 '23: -29.6M Q3 '23: -31.3M Q4 '23: -37.8M Q1 '24: -33.8M Q2 '24: -28.1M Q3 '24: -26.3M Q4 '24: -31.3M Q1 '25: -33.3M Q2 '25: -24.4M Q3 '25: -15.2M Q4 '25: -17.8M Q1 '26: -26.8M Q2 '26: -22.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -51.8M Q4 '21: 38.7M Q1 '22: -41.4M Q2 '22: -49.1M Q3 '22: -36.3M Q4 '22: -38.5M Q1 '23: -34.1M Q2 '23: -32.6M Q3 '23: -34.5M Q4 '23: -41.8M Q1 '24: -37.4M Q2 '24: 23.8M Q3 '24: -32.1M Q4 '24: -30.8M Q1 '25: -23.5M Q2 '25: -37.3M Q3 '25: -33.1M Q4 '25: -102.2M Q1 '26: -22.4M Q2 '26: -67M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 350K 700K 1.1M Q3 '19: 1M Q3 '19

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -24M Q4 '21: 25.5M Q1 '22: -59.2M Q2 '22: -35.1M Q3 '22: -28.4M Q4 '22: -26.8M Q1 '23: -18.9M Q2 '23: -25.7M Q3 '23: -29.5M Q4 '23: -18.6M Q1 '24: -43.7M Q2 '24: -38.5M Q3 '24: -19.5M Q4 '24: -25.8M Q1 '25: -39M Q2 '25: -18.7M Q3 '25: -5.9M Q4 '25: -11.8M Q1 '26: -22.7M Q2 '26: -24.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '21: -52.9M Q2 '21: -55.7M Q3 '21: -24M Q4 '21: 25.3M Q1 '22: -59.3M Q2 '22: -35.1M Q3 '22: -28.4M Q4 '22: -26.8M Q1 '23: -18.9M Q2 '23: -25.7M Q3 '23: -29.5M Q4 '23: -18.6M Q1 '24: -43.9M Q2 '24: -38.5M Q3 '24: -19.5M Q4 '24: -25.9M Q1 '25: -39M Q2 '25: -18.7M Q3 '25: -5.9M Q4 '25: -11.8M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '21: 75.2M Q3 '21: 75.5M Q1 '22: 77.6M Q2 '22: 79.7M Q3 '22: 80.2M Q1 '23: 113.5M Q2 '23: 114.2M Q3 '23: 114.4K Q1 '24: 7.7K Q2 '24: 10.3K Q3 '24: 8.3K Q1 '25: 8.5K Q2 '25: 8.6K Q3 '25: 8.7K Q1 '26: 24.7K Q2 '26: 28.9K Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '18: -2.97 Q4 '18: -3.13 Q1 '19: -3.44 Q2 '19: -3.55 Q3 '19: -3.43 Q4 '19: -3.23 Q1 '20: -2.92 Q2 '20: -2.84 Q3 '20: -2.90 Q4 '20: -2.72 Q1 '21: -2.71 Q2 '21: -2.79 Q3 '21: -2.75 Q4 '21: -1.65 Q1 '22: -1.41 Q2 '22: -1.32 Q3 '22: -1.08 Q4 '22: -2.02 Q1 '23: -1.79 Q2 '23: -1.46 Q4 '18 Q3 '19 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.